Literature DB >> 8309355

Experimental infection of Chlamydia pneumoniae in mice.

S S Kaukoranta-Tolvanen1, A L Laurila, P Saikku, M Leinonen, L Liesirova, K Laitinen.   

Abstract

NIH/S, Swiss Webster, and BALB/c mice were infected intranasally with three Chlamydia pneumoniae isolates, Kajaani 6, Helsinki 12, and TW-183. C. pneumoniae could be isolated from the lung homogenates and bronchoalveolar lavage fluids up to the third week post-infection. Specific serum IgG antibodies against C. pneumoniae reached high levels in the third week and remained elevated until the end of the 6-week follow-up period. Serum IgM levels were highest in the third week post-infection and started to decrease thereafter. In spite of these signs of ongoing infection, the mice did not show any symptoms of disease. NIH/S mice could be readily and uniformly infected, while BALB/c mice were the most resistant and developed the weakest antibody response. The greatest histological changes were detected in NIH/S mice as well. The inflammatory infiltrate, which consisted of lymphocytes and plasma cells throughout the study, was restricted to the peribronchial and perivascular space and to the interstitium of the lung parenchyma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8309355     DOI: 10.1006/mpat.1993.1079

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  16 in total

1.  Chlamydia pneumoniae infection in polarized epithelial cell lines.

Authors:  Liisa Törmäkangas; Eveliina Markkula; Kari Lounatmaa; Mirja Puolakkainen
Journal:  Infect Immun       Date:  2010-03-29       Impact factor: 3.441

2.  Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge.

Authors:  J M Vuola; V Puurula; M Anttila; P H Mäkelä; N Rautonen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

4.  Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice.

Authors:  J M Penttilä; M Anttila; K Varkila; M Puolakkainen; M Sarvas; P H Mäkelä; N Rautonen
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

5.  Chlamydophila pneumoniae re-infection triggers the production of IL-17A and IL-17E, important regulators of airway inflammation.

Authors:  Tímea Mosolygó; József Korcsik; Emese Petra Balogh; Ildikó Faludi; Dezső P Virók; Valéria Endrész; Katalin Burián
Journal:  Inflamm Res       Date:  2013-02-06       Impact factor: 4.575

6.  Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model.

Authors:  Ulla Airaksinen; Tuula Penttilä; Eva Wahlström; Jenni M Vuola; Mirja Puolakkainen; Matti Sarvas
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

7.  Local immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfection.

Authors:  J M Penttilä; M Anttila; M Puolakkainen; A Laurila; K Varkila; M Sarvas; P H Mäkelä; N Rautonen
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

8.  Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents.

Authors:  N D Masson; C D Toseland; A S Beale
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment.

Authors:  K Laitinen; A L Laurila; M Leinonen; P Saikku
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

10.  Expansion of a novel pulmonary CD3(-) CD4(+) CD8(+) cell population in mice during Chlamydia pneumoniae infection.

Authors:  J M Penttilä; R Pyhälä; M Sarvas; N Rautonen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.